Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease

Figure 2 Time-dependent receiver operating characteristic curves of four noninvasive scoring systems for predicting de novo hepatocellular carcinoma at 1-year, 3-year, 5-year, and 8-year follow-up. A: 1-year follow-up; B: 3-year follow-up; C: 5-year follow-up; D: 8-year follow-up. ALBI: Albumin-bilirubin score; aMAP: Age-male-albumin-bilirubin-platelet score; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis-4 index; ROC: Receiver operating characteristic; FU: Follow-up.